I think we're both thinking about the same thing. Perhaps I should have said "the ultimate effector of a particular disease process" rather than "particular pathway." If I can make that amendment, then hemophilia treatment with FVIII fits the bill exactly.
I'm not sure that use of anti-TNFs in inflammatory diseases fits the key precept as TNF is not the only (or even the primary) mediator of inflammation. Moreover, as you know, most intra- and extra-cellular signalling pathways are a cascade; inhibiting TNF production upstream could have lots of unintended consequences.
Market Data 
Markets 
AI
